Avicenna gets patent for ROCK inhibitor compounds for ALS, more
Avicenna Biosciences has received its first patent covering new ROCK inhibitor compounds that may be used to treat amyotrophic…
Articles by Esteban Dominguez Cerezo, MS
CXCL12 levels in spinal fluid may improve ALS diagnosis accuracy
Measuring the levels of a novel protein biomarker called C-X-C motif chemokine ligand 12 — CXCL12 for short —…
S-oxprenolol granted orphan drug status by FDA as ALS treatment
S-oxprenolol, an investigational therapy being developed by Actimed Therapeutics to treat muscle wasting in amyotrophic lateral sclerosis (ALS), has…
EverythingALS launches new app version for broader ALS community
EverythingALS has launched a new version of its mobile app that now includes community support, artificial intelligence-powered chat assistance,…
Bill targets research on environmental factors and ALS
Two U.S. representatives have introduced legislation that would establish a federally funded research program to study the link between environmental…
Dewpoint’s TDP-43-targeted ALS therapy gains further support
Dewpoint Therapeutics has won a second grant from Target ALS Foundation to advance preclinical studies of its experimental…
New initiative aims to advance patient-derived ALS cell models
A consortium of amyotrophic lateral sclerosis (ALS) nonprofits and industry stakeholders has launched Project Mosaic, an initiative that…
C-Path grant aids work into way of protecting nerve cells in ALS
A researcher at Penn State University has received a $250,000 grant for an innovative project that seeks to identify and…
I AM ALS coalition aims for neurodegenerative disease unity
Estimates from the World Health Organization suggest 1 in 4 people are likely to be diagnosed with a neurodegenerative condition.
Diamir granted EU patent for use of microRNAs toward ALS diagnosis
Diamir Biosciences has received a patent in the European Union that covers the use of microRNAs (miRNAs), that is,…